Showing results (91-100 of 111) with videos related to
Sort By:
Pageof 12
Neurology|February 13, 2025
Long-Term Dynamics of CSF and Serum Neurofilament Light Chain in Adult Patients With 5q Spinal Muscular Atrophy Treated With NusinersenIsabell Cordts, Cornelia Fuetterer, Annika Wachinger, et al.JAMA Oncology|March 6, 2025
Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy: The POLAR Randomized Clinical TrialLaura L Michel, Daniel Schwarz, Philipp Romar, et al.International Journal of Molecular Sciences|November 27, 2024
Identification of Biochemical Determinants for Diagnosis and Prediction of Severity in 5q Spinal Muscular Atrophy Using <sup>1</sup>H-Nuclear Magnetic Resonance Metabolic Profiling in Patient-Derived BiofluidsAfshin Saffari, Moritz Niesert, Claire Cannet, et al.Orphanet Journal of Rare Diseases|October 21, 2021
<sup>1</sup>H-NMR-based metabolic profiling identifies non-invasive diagnostic and predictive urinary fingerprints in 5q spinal muscular atrophyAfshin Saffari, Claire Cannet, Astrid Blaschek, et al.Neurology and Therapy|December 16, 2022
Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of EplontersenTeresa Coelho, Márcia Waddington Cruz, Chi-Chao Chao, et al.Annals of Clinical and Translational Neurology|April 1, 2021
Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatmentMaren Freigang, Claudia D Wurster, Tim Hagenacker, et al.Journal of Neuromuscular Diseases|July 12, 2024
Smartphone-Based Assessment of Mobility and Manual Dexterity in Adult People with Spinal Muscular AtrophyEduardo Arteaga-Bracho, Gautier Cosne, Christoph Kanzler, et al.European Journal of Neurology|May 7, 2021
Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersenThomas Meyer, André Maier, Zeljko Uzelac, et al.Proceedings of the National Academy of Sciences of the United States of America|December 25, 2013
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapyMarkus Weiler, Jonas Blaes, Stefan Pusch, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2024
Cerebrospinal Fluid cfDNA Sequencing for Classification of Central Nervous System GliomaFlorian Iser, Felix Hinz, Dirk C Hoffmann, et al.Pageof 12